The permanent adoption of eCOA is a natural step in the industry-wide effort to create a more patient-centric clinical trial experience. Learn more in the available blog.

A Japan-based pharmaceutical development company utilized Signant's eCOA solutions and knowledge to ensure the reliability of endpoints in their Phase 3 and extended-duration CNS trials.

In this webinar, explore the importance of eCOAs, how they have evolved from the standard paper diaries, and what efficiencies you can realize from them.

Understand how the informed consent process ensures trial participants are adequately educated about the trial and what's required of them during the process while confirming their willingness to enroll.

See how a team of four managed data for 40 peer-reviewed studies and 200,000 participants.

What are the specific tools and keys to conduct eCOA trials in oncology successfully? This article identifies some of the relevant solutions to tackle oncology protocol complexities.

Dive into the prediction that the rapid adoption of eCOAs will continue to grow in 2022, as sponsors acknowledge how useful these tools have become in decentralized clinical trial (DCT) settings.

This comprehensive overview highlights the critical role these platforms play in modern clinical research, emphasizing their impact on data integrity and trial efficiency.

Discover how an instruction program directly contributed to significantly lowering the placebo response rate in a phase III migraine CNS study.